Results 171 to 180 of about 55,899 (275)

Mucosal Melanoma

, 2019
Michael A. Henderson, Charles M. Balch, Claus Garbe, Alexander N. Shoushtari, Bin Lian, Chuanliang Cui, Jun Guo   +6 more
openaire   +2 more sources

Sinonasal mucosal melanoma of the maxillary sinus: Diagnostic challenges and therapeutic insights from a case report. [PDF]

Radiol Case Rep
Chatar CEM, Benabdallah A, Zouiti ZE, Tsen AE.   +3 more
europepmc   +1 more source

Treatment options for immune‐related adverse events associated with immune checkpoint inhibitors

British Journal of Pharmacology, Volume 183, Issue 6, Page 1271-1287, March 2026.
Abstract The immunotherapy revolution with the use of immune checkpoint inhibitors (ICIs) started with the clinical use of the first ICI, ipilimumab, in 2011. Since then, the field of ICI therapy has rapidly expanded — with the FDA approval of 10 different ICI drugs so far and their incorporation into the therapeutic regimens of a range of malignancies.
Yu Hua Chen, Tamás Kovács, Péter Ferdinandy, Zoltán V. Varga   +3 more
wiley   +1 more source

Dermatologic Features of Endocrine Tumor Syndromes—Systematic Review and Meta‐Analysis

International Journal of Dermatology, Volume 65, Issue 3, Page 464-488, March 2026.
ABSTRACT Endocrine tumor syndromes, including multiple endocrine neoplasia types 1, 2A, and 2B (MEN1, MEN2A, MEN2B), Carney complex (CNC), and PTEN hamartoma tumor syndrome (PHTS), are hereditary conditions characterized by multisystem tumor development.
Sára Pálla, Zseraldin Metyovinyi, Fanni Adél Meznerics, Arash Mirzahosseini, Judit Tőke, Miklós Tóth, Henriett Butz, Attila Patócs, Márta Medvecz   +8 more
wiley   +1 more source

Mucosal Melanoma of the Oral Cavity: Prognostic Factors Influencing Patient Survival Outcomes. [PDF]

J Clin Med
Tarnawski J, Wojciechowska B, Polcyn A, Garbacewicz Ł, Drogoszewska B, Michcik A.   +5 more
europepmc   +1 more source

Evaluating VEGFR2 as a Target for Anti‐Tumour Therapy in Canine Melanoma

Veterinary and Comparative Oncology, Volume 24, Issue 1, Page 95-104, March 2026.
ABSTRACT Vascular endothelial growth factor receptor 2 (VEGFR2) is a key target for anti‐angiogenic oncotherapy, as inhibiting this receptor on tumour vasculature slows tumour development and enhances drug‐ and immune infiltration, improving therapy outcome.
Esther Hindriks, Wilhelmina Bergmann, Aitor Martínez Ruiz, Maurice M. J. M. Zandvliet, Alice J. A. M. Sijts, Femke Broere   +5 more
wiley   +1 more source

Specific oncogene activation of the cell of origin in mucosal melanoma. [PDF]

Nat Commun
Babu S, Chen J, Baron CS, Sun K, Robitschek E, McConnell AM, Wu C, Dedeilia A, Sade-Feldman M, Modhurima R, Manos MP, Chen KY, Cox AM, Ludwig CG, Kellis M, Buchbinder EI, Hacohen N, Yang J, Boland GM, Abraham BJ, Liu D, Zon LI, Insco ML.   +22 more
europepmc   +1 more source

Sinonasal Tract Mucosal Melanoma [PDF]

Ear, Nose & Throat Journal, 2014
openaire   +2 more sources

A Comparative Study of Melanocytic Tumours: Linking Portuguese Dogs and Cats to Human Cases

Veterinary and Comparative Oncology, Volume 24, Issue 1, Page 105-120, March 2026.
ABSTRACT Melanocytic tumours (MT) occur in both humans and companion animals, presenting an opportunity for comparative oncology research. Thus, this study provides a comprehensive epidemiological analysis comparing MT in Portuguese dogs, cats and humans. Data were obtained from the Portuguese National Cancer Registry (RON) (2011–2021) and Vet‐OncoNet (
Catarina Alves Pinto, Ana Isabel Ribeiro, João Niza‐Ribeiro, Carlos Alberto Palmeira de Sousa, Katia Pinello, Andreia Alexandra Ferreira Santos   +5 more
wiley   +1 more source

Targeting the Notch1‐YY1‐ICAM1 Signaling Axis Enhances the Efficacy of Immunotherapy in HCC by Activating CD8+ T‐Cell‐Driven Cancer Cell Pyroptosis

Advanced Science, Volume 13, Issue 7, 3 February 2026.
In hepatocellular carcinoma (HCC), aberrantly activated Notch1 signaling induces its target gene YY1, which impairs immunotherapy efficacy by suppressing tumor cell‐ICAM1‐driven T cell activation and the mediated pyroptosis of T cells against tumor cells.
Ke Zhu, Fa‐Peng Zhang, Chao Qin, Zhi‐Xiao Song, Cai‐Ni Yang, Shu‐Sheng Lin, Xian‐Huan Yu, Wen‐Rui Wu, Chao‐Qun Liu, Chao Liu, Lei‐Bo Xu   +10 more
wiley   +1 more source